New CGT Catapult Advisory Board Addresses Advanced Therapy Deployment Challenges

A newly established Cell and Gene Therapy Catapult (CGT Catapult) technology advisory board, announced in February 2026, aims to identify emerging technological opportunities and address persistent barriers that limit large-scale adoption of advanced therapy medicinal products (ATMPs). This initiative reflects growing industry recognition that scientific progress in cell and gene therapies (CGTs) must be matched by advances in manufacturing, digital infrastructure, regulatory alignment, and treatment delivery models.¹

The independent advisory body will provide strategic guidance to support technology deployment across the advanced therapies ecosystem. The board’s responsibility spans data and digital innovation, manufacturing and supply technologies, product characterization and analytical testing, and the development of novel patient treatment pathways.

According to CGT Catapult, these focus areas collectively represent key operational constraints that continue to influence commercialization timelines and healthcare system integration for CGTs.

Why are technology integration challenges limiting advanced therapy adoption?

Despite rapid clinical progress across gene editing, engineered cell therapies, and regenerative medicine platforms, industry stakeholders continue to encounter scalability and implementation challenges beyond clinical development. Manufacturing complexity, fragmented data environments, and evolving regulatory expectations remain significant contributors to delayed adoption.²

The new advisory board brings together experts from academia, regulatory agencies, and industry leadership to evaluate how emerging technologies can improve efficiency and accessibility across therapy development and delivery.

Chairing the board is Phil Vanek, PhD, founder of Redline Bioadvisors and chief commercialization officer at the International Society for Cell & Gene Therapy. Additional members include former regulators, biotechnology executives, digital infrastructure specialists, and synthetic biology researchers. This diversity reflects the increasingly multidisciplinary requirements of advanced therapy commercialization.

“CGT Catapult has played a critical role in shaping the advanced therapy landscape for more than a decade, and I’m grateful for the opportunity to join the advisory board at this inflection point,” Dr. Vanek said in a press release.¹ “As the industry continues to evolve and advance, we need to turn our attention to driving efficiency, adoption, and access. I look forward to working with this advisory board to help identify strategies to accomplish these goals, both in the [United Kingdom] and around the world.”

How could a coordinated technology strategy accelerate global ATMP deployment?

The establishment of the advisory board signals a shift toward system-level innovation aimed at enabling routine clinical implementation of advanced therapies. As treatment modalities move from individualized experimental interventions toward broader commercial availability, alignment across manufacturing systems, digital data management, and regulatory inspection frameworks becomes increasingly critical.³

By identifying technology-driven opportunities and potential roadblocks early, the board is expected to inform strategic investment priorities and operational models supporting scalable therapy delivery.

According to Matthew Durdy, chief executive of CGT Catapult, the organization’s role is increasingly focused on anticipating infrastructure needs required for sector growth. “Our role is to meet the technology and innovation needs of the industry,” he said in the release.¹ “We are privileged and grateful that this extraordinary group of people have agreed to support us. They will guide us through the challenges and opportunities to ensure that the exceptional benefits [of advanced therapies] reach more people.”

What does this initiative mean for advanced therapy commercialization?

Industry efforts to expand patient access to ATMPs increasingly depend on cross-sector coordination rather than isolated scientific advances. Initiatives such as CGT Catapult’s new technology advisory board highlight growing emphasis on digital transformation, standardized testing approaches, and manufacturing innovation as enabling factors for sustainable market expansion.¹

As advanced therapies transition toward broader healthcare adoption, organizations are prioritizing collaborative governance models capable of bridging research innovation with real-world clinical implementation.^2,3 CGT Catapult’s initiative represents one such effort to align technological progress with scalable delivery pathways across global advanced therapy markets.

References

1. CGT Catapult. CGT Catapult establishes Technology Advisory Board to identify opportunities for the advanced therapies sector to deploy and benefit from innovations. Press Release. Feb. 19, 2026.
2. FDA. Guidance Documents for Rare Disease Drug Development. Updated Feb. 23, 2026. Accessed Feb. 25, 2026. https://www.fda.gov/drugs/guidances-drugs/guidance-documents-rare-disease-drug-development
3. Cromos Pharma. Regulatory Pathways for Rare Disease Drug Development: What Sponsors Need to Know – Rare Disease Day Special. Feb. 27, 2025. Accessed Feb. 25, 2026. https://cromospharma.com/regulatory-pathways-for-rare-disease-drug-development/